Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus carboplatin/paclitaxel vs placebo plus carboplatin/paclitaxel in metastatic squamous NSCLC
CTR20170044Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in Pulmonary squamous cell carcinoma, sponsored by Merck & Co.. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20170044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170044.